Trial Profile
An open label, randomized, comparative study of Zerit (d4T) [stavudine] + Epivir (3TC) [lamivudine] + Crixivan [indinavir] versus Retrovir (AZT) [zidovudine] + Epivir (3TC) + Crixivan in HIV-infected, antiretroviral naive subjects with CD4 cell counts of 200 - 700 cells/mm3 and HIV RNA baseline copy number of greater than or equal to 10,000 copies/ml
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Indinavir (Primary) ; Lamivudine (Primary) ; Stavudine (Primary) ; Zidovudine (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 19 Dec 2006 Status change
- 21 Oct 2005 New trial record.